How long does protection last after a single malaria vaccine dose?
Part of Infections clinical trials.
This trial checks how long protection lasts in people who already got a single dose of a new malaria vaccine (GA2 sporozoites) and were protected from infection. If you were in the earlier CoGA study and were protected, you may be invited to see if that protection is still working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 35 years old and in good health.
- You must have been in the earlier CoGA study, received the GA2 sporozoite shot, and were protected during a malaria challenge.
- If you are of childbearing age, you must use reliable birth control and not breastfeed during the study.
- You cannot have taken part in any other malaria study or had malaria before.
- You must not be allergic to mosquito bites or to the anti-malaria drugs used in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of experimental malaria vaccines to see if they are safe and help protect against malaria. It includes both adults and young children in malaria-affected areas.
This trial uses a genetically modified malaria parasite given by mosquito bite to safely test a new vaccine approach in healthy volunteers. If you qualify, you'll help researchers understand how the body defends against malaria.
This study tests a new malaria vaccine in healthy adults. You will receive the vaccine and then be exposed to the malaria parasite in a controlled setting to check if the vaccine protects you.
This Phase 1/2 study tests a new vaccine meant to protect young children against malaria. If you qualify, your baby would get the study vaccine and be followed for about 12 months to check safety and early signs of protection.
This is an early-stage safety study testing a new experimental drug (GSK4425689A) in healthy volunteers. Researchers want to find safe doses and understand how the body processes this medication.
This study tests a new long-acting malaria prevention injection (MMV371) in healthy adults and adolescents in Rwanda. Researchers will monitor how safe it is and how your body processes it over 24 weeks.
Hear when a new Malaria Falciparum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.